The preferred targeted therapy for left-sided RAS wild-type metastatic colorectal cancer, in combination with standard chemotherapy, is panitumumab, not bevacizumab, based on a head-to-head comparison in the phase III PARADIGM trial. Panitumumab plus chemotherapy yielded the longest overall survival ever reported in a prospective phase III trial in first-line metastatic colorectal cancer. Takayuki Yoshino, MD, PhD, of the National Cancer Center Hospital East, Chiba, Japan, presented the data at the Plenary Session of the 2022 ASCO Annual Meeting. The use of panitumumab, which is an inhibitor of EGFR, improved overall survival by 3.6 months as compared with the VEGF inhibitor bevacizumab. Median overall survival was 37.9 months vs 34.3 months, respectively.
展开▼
